Navigation Links
IV Aspirin Drip Appears to Be Safe, Effective for Migraine
Date:9/20/2010

MONDAY, Sept. 20 (HealthDay News) -- The intravenous administration of aspirin appears to be a safe and effective way to treat hospitalized patients suffering from either severe headaches or migraines, new research indicates.

Study author Dr. Peter J. Goadsby, of the Headache Group in the department of neurology at the University of California, San Francisco, described his team's findings in the Sept. 21 issue of Neurology.

"Intravenous aspirin is not readily available in the United States, and only on a 'named patient' basis in the United Kingdom," Goadsby noted in a news release from the American Academy of Neurology. The 'named patient' program is for those who have exhausted approved treatment options and do not qualify for a clinical trial.

Pointing out that use of intravenous (IV) aspirin is not uncommon in other parts of continental Europe, Goadsby added that his team's results "show it could be a cost-effective, safe and easy-to-use treatment for people hospitalized for headache or migraine."

To explore the IV aspirin treatment option, the study authors focused on 168 patients (including 117 women) between the ages of 18 and 75 who had been hospitalized for severe headaches or migraines. All were given 1 gram of aspirin via a drip, for an average of five doses.

Most of the patients had been diagnosed with a migraine, and almost all were also diagnosed with a "chronic daily headache," meaning that they had suffered from a headache for at least 15 days out of each of the prior three months.

All of the patients knew they were being treated with aspirin. And each study participant kept a pain diary during the process, rating pain on a 10-point scale ranging from mild to moderate to severe.

The researchers found that in more than 25 percent of the treatments, the IV aspirin caused pain to drop down a full category, namely from severe to moderate, moderate to mild, or mild to no headache.

About 40 percent of treatments had a "moderate effect" on participants' pain levels, the findings showed.

Side effects from the treatment included heartburn, nausea, vomiting, bleeding, worsening of asthma, kidney impairment and rash.

"Our findings warrant more research into the use of IV aspirin for severe headache or migraine," Goadsby stated in the news release.

Although Goadsby noted that prior research had similarly illustrated the apparent benefits of IV aspirin by comparing pain levels against a second pool of patients who did not get the treatment, Dr. Carl Stafstrom, a professor of neurology and pediatrics at the University of Wisconsin-Madison, pointed out that the current effort did not do so.

"And certainly I would want to see this approach tested with such a 'control group' to make sure that the treatment is truly safe as well as effective," Stafstrom cautioned.

"But it's an encouraging response," he added. "And there's certainly a need for new and improved treatment modalities for acute headaches among hospitalized patients. So I would say that any new treatment is welcome. But this needs more exploration."

More information

For more on migraine and headache treatment, visit the American Academy of Family Physicians.

-- Alan Mozes

SOURCES: American Academy of Neurology, news release, Sept. 14, 2010; Carl Stafstrom, M.D., Ph.D., professor, neurology and pediatrics, University of Wisconsin-Madison


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Aspirin May Boost Breast Cancer Survival
2. Cardiologists Comment on Aspirin Versus Resveratrol
3. Aspirin Alone Works Best to Prevent Clots a Year After Stenting
4. Aspirin May Increase Risk of Crohns Disease
5. Experts Advise At-Risk Diabetics to Begin Daily Aspirin Later
6. Aspirin recommendations changed for many younger diabetic patients
7. Can aspirin prolong a healthy life?
8. Low-Dose Aspirin May Reduce Colon Cancer Risk
9. Protein Appears Key to Intestinal Balance
10. How health care is paid for appears to impact outcome
11. Hospitalization Appears to Help Personality Disorder Patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
IV Aspirin Drip Appears to Be Safe, Effective for Migraine
(Date:2/22/2017)... ... February 22, 2017 , ... ... newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. This ... instant absorption from the mouth into the bloodstream. Far outpacing the ...
(Date:2/22/2017)... ... 22, 2017 , ... The Centers for Medicare & Medicaid ... in Delaware, New Jersey, Pennsylvania and West Virginia prepare for and participate in ... Act of 2015 (MACRA). , This technical assistance, authorized and funded under ...
(Date:2/22/2017)... NJ (PRWEB) , ... February 22, 2017 , ... ... healthcare communications company, launched a new media platform connecting healthcare technology professionals and ... will be followed by a quarterly publication starting on March 1, announced Michael ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pet obesity in the U.S. continued ... according to the Association for Pet Obesity Prevention (APOP). During the ninth annual survey, ... such as the benefits of corn and grains, value of raw and organic diets, ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... so many different solutions on the market, it is easy to start feeling ... Premier Locksmith offers a complimentary security consultation. , Home Security Hardware Choices, ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... , Feb. 22, 2017 Henry ... an exclusive distribution agreement with Rijuven, which develops ... diagnostic device to medical practitioners. ... electrocardiogram (ECG) and heart sound signals, transmits real-time ... and offers cloud-based analysis to help physicians provide ...
(Date:2/22/2017)... Calif. , Feb. 22, 2017  Bioness, Inc., ... therapies, today announced the first series of successful StimRouter ... at Radboud University Medical Center (Nijmegen, Netherlands ... ( Cork, Ireland ), and Kliniek Park ... the successful launch continuing, Bioness plans to further support ...
(Date:2/22/2017)... , Feb. 22, 2017 Oncternal Therapeutics, ... for both rare and common malignancies, today announced ... financing. The company intends to use the proceeds ... TK216, and to advance preclinical development of a ... Cirmtuzumab is a first-in-class anti-ROR1 monoclonal antibody being ...
Breaking Medicine Technology: